IL314176A - Compositions and methods for treating depression - Google Patents

Compositions and methods for treating depression

Info

Publication number
IL314176A
IL314176A IL314176A IL31417624A IL314176A IL 314176 A IL314176 A IL 314176A IL 314176 A IL314176 A IL 314176A IL 31417624 A IL31417624 A IL 31417624A IL 314176 A IL314176 A IL 314176A
Authority
IL
Israel
Prior art keywords
patient
depression
depressive disorder
major depressive
identified
Prior art date
Application number
IL314176A
Other languages
English (en)
Hebrew (he)
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of IL314176A publication Critical patent/IL314176A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869Interleukin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4737C-reactive protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/525Tumor necrosis factor [TNF]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/54Interleukins [IL]
    • G01N2333/5412IL-6

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Otolaryngology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL314176A 2022-01-10 2023-01-09 Compositions and methods for treating depression IL314176A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263298060P 2022-01-10 2022-01-10
PCT/IB2023/050171 WO2023131921A1 (en) 2022-01-10 2023-01-09 Compositions and methods for the treatment of depression

Publications (1)

Publication Number Publication Date
IL314176A true IL314176A (en) 2024-09-01

Family

ID=84981673

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314176A IL314176A (en) 2022-01-10 2023-01-09 Compositions and methods for treating depression

Country Status (10)

Country Link
US (1) US20250064779A1 (https=)
EP (1) EP4463143A1 (https=)
JP (1) JP2025503649A (https=)
KR (1) KR20240132501A (https=)
CN (1) CN118843459A (https=)
AU (1) AU2023206048A1 (https=)
CA (1) CA3247733A1 (https=)
IL (1) IL314176A (https=)
MX (1) MX2024008619A (https=)
WO (1) WO2023131921A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19723133A1 (de) 1997-06-03 1998-12-10 Caideil M P Teoranta Tourmakea Austragvorrichtung für Medien
WO2009094260A1 (en) * 2008-01-22 2009-07-30 Eli Lilly And Company Kappa selective opioid receptor antagonist
JP2022548233A (ja) * 2019-09-13 2022-11-17 ヤンセン ファーマシューティカルズ,インコーポレーテッド エスケタミンの鼻腔内投与

Also Published As

Publication number Publication date
EP4463143A1 (en) 2024-11-20
MX2024008619A (es) 2024-09-25
KR20240132501A (ko) 2024-09-03
CN118843459A (zh) 2024-10-25
JP2025503649A (ja) 2025-02-04
US20250064779A1 (en) 2025-02-27
WO2023131921A1 (en) 2023-07-13
CA3247733A1 (en) 2023-07-13
AU2023206048A1 (en) 2024-08-29

Similar Documents

Publication Publication Date Title
Kaji et al. Effect of ultrahigh‐dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: A double‐blind controlled study
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
EP2730659A3 (en) Treatment and Prophylaxis of Amyloidosis
BRPI0507442B8 (pt) método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia
BR0213100A (pt) Combinações para o tratamento de distúrbios imuniinflamatórios
BR112022005757A2 (pt) Uricase aperfeiçoada e método de tratamento de hiperuricemia usando a mesma
BR112022007010A2 (pt) Terapia gênica para doença de alzheimer
MX2023006598A (es) Biomarcadores agonistas del trem2 y métodos para usarlos.
MA62935B1 (fr) Méthodes de traitement ou de prévention de l'amyotrophie spinale
Villanueva-Ruiz et al. Manual therapy and neck-specific exercise are equally effective for treating non-specific neck pain but only when exercise adherence is maximised: a randomised controlled trial
IL314176A (en) Compositions and methods for treating depression
Matsumoto et al. Stimulating angiogenesis mitigates the unloading‐induced reduction in osteogenesis in early‐stage bone repair in rats
BR112022015057A2 (pt) Métodos e composições para melhorar ou prevenir uma doença ou condição de doença, para melhorar o envelhecimento ou impactar o processo de envelhecimento, métodos para um tratamento de câncer e para prevenção de câncer, e, composição para tratamento ou prevenção de câncer
BRPI0512503A (pt) composição que compreende ácido lático e lactoferrina
Kedzior et al. Challenges in comparing the acute cognitive outcomes of high-frequency repetitive transcranial magnetic stimulation (HF-rTMS) vs. electroconvulsive therapy (ECT) in major depression: a systematic review
IL314179A (en) Compositions and methods for the treatment of depression
MX2021009862A (es) Metodos para obtener celulas de musculo liso inducidas.
MX2023014113A (es) Biomarcadores agonistas de trem2 y métodos para usarlos.
WO2020061067A3 (en) Compositions and methods for treating bone injury
BR112022025901A2 (pt) Composições e métodos para tratar transtorno obsessivo-compulsivo
Hrkač et al. Early cyclophosphamide treatment in new-onset progressive cutaneous systemic sclerosis–a case report and literature review
WO2019066548A3 (ko) 심부전의 예방 또는 치료용 약학적 조성물
Rasmussen Electroconvulsive therapy versus transcranial magnetic stimulation for major depression: a review with recommendations for future research
EP4474474A3 (en) Methods and compositions for the treatment of osteopetrosis
Essafi et al. AB0832 The effects of anti-tnf biological agents in patients with spondyloarthritis: a comparative study